The companies are hard at work generating the additional requested CMC data, Venatorx CEO Christopher Burns said in a prepared statement
BPC-157 is better suited for injury recovery, inflammation, and healing damaged tissues
this decrease resulted in reduced TCA cycle flux, leading to a decrease in precursors and energy for protein synthesis
Okay, sure, it doesnt exactly roll off the tongue, but as a weight loss medication, its kicking ass in clinical trials
CD68: cluster of differentiation 68, EX-4: exendin-4, LAMP1: lysosomal-associated membrane protein 1, TZP: tirzepatide